The Role of Ischemia Reperfusion Damage on Renal Transplant, what are the new treatments?
Journal of Pediatric Nephrology,
Vol. 1 No. 1 (2013),
24 July 2013
,
Page 8-17
https://doi.org/10.22037/jpn.v1i1.4343
Abstract
How to Cite This Article: Otukesh H, Hoseini R, Rahimzadeh N, Hosseini S, Ahmadpoor P, Javadi Larijani F. The role of Ischemia reperfusion damage on renal transplant, what are the new treatments? J Ped. Nephrology 2013 July;1(1):1-7.
Ischemia reperfusion damage usually occurs after renal transplantation. These injuries can stimulate the innate immune system, trigger an inflammatory response and ultimately activate the adaptive immune system. These events may result in rejection, graft fibrosis and chronic allograft nephropathy.
Different mechanisms contribute to innate immune system activation following ischemia reperfusion injury in renal transplants. Some of these mechanisms are known and described by investigators while the remaining are still unknown.
To clarify the precise mechanisms underlying the innate immune system activation and rejection progression helps us to plan therapeutic protocols to reduce immunologic responses to ischemic events and to improve the graft function and outcome. In this review, we will discuss how innate and adaptive immune systems are activated during an ischemic insult and thereafter discuss related therapeutic interventions to block the activating pathways.
Keywords: Ischemia; Renal transplantation; Reperfusion.
How to Cite
References
Terasaki PI, Cecka MJ, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333: 333-336.
Lehtonen SR, Isoniemi HM, Salmela KT, Taskinen EI, von Willebrand EO, Ahonen JP. Long-term graft outcome is not necessarily affected by delayed onset of graft function and early acute rejection. Transplantation 1997; 64:103−107.
Nicholson ML, Wheatley TJ, Horsburgh T, Edwards CM, Veitch PS, Bell PR. The relative influence of delayed graft function and acute rejection on renal transplant survival. Review Transplant Int 1996;9:415−419.
Giral-Classe M, Hourmant M, Cantarovich D, Dantal J, Blancho G, Daquin P. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int 1998;54:972–978.
Gianello P, Carlier M, Jamart J, et al. Effect of 1-28 alpha-h atrial natriuretic peptide on acute renal failure in cadaveric renal transplantation. Clin Transpl 1995; 9: 481−489.
Loverre A, Capobianco C, Stallone G, et al. Ischemia-reperfusion injury-induced abnormal dendritic cell traffic in the transplanted kidney with delayed graft function. Kidney Int 2007;72:994–1003.
Martins P, Chandraker A, Tullius SG. Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment. Transplan int 2006;19(5):351–359.
Takeda K, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.
Lu YC, Penfield JG, Kielar ML, Vazquez MA, Jeyarajah DR. Hypothesis: Is renal allograft rejection initiated by the response to injury sustained during the transplant process? Kidney International 1999;55: 2157–2168.
Halloran P, Aprile M, Farewell V. Factors influencing early renal function in cadaver kidney transplants: A case-control study. Transplantation 1988; 45: 122−127.
Cosio FG, Pelletier RP, Falkenhain ME, et al. Impact of acute rejection and early allograft function on renal allograft survival. Transplantation 1997; 63:1611−1615.
Held PJ, Kahan BD, Hunsicker LG, et al. The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med 1994; 331:765−770.
Requião-Moura LR, de Souza Durão M, Tonato EJ, et al. Effects of ischemia and reperfusion injury on long-term graft function. Transplant Proc 2011;43(1):70-3.
Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol 2009;130 (1): 41–50.
Noris M, Cassis P, Azzollini N, et al. The Toll-IL-1R Member Tir8/SIGIRR Negatively Regulates Adaptive Immunity against Kidney Grafts. The Journal of Immunology 2009;183(7):4249-4260.
Wolfs TG, Buurman WA, van Schadewijk A, et al. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol 2002;168:1286–1293.
Kim BS, Lim SW, Li C, et al. Ischemia-reperfusion injury activates innate immunity in rat kidneys.Transplantation 2005;79:1370–1377.
Leemans JC, Stokmani G, Claessen N, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney, J Clin Invest 2005;115(10):2894–2903.
Sharland, S. Chadban. TLR4 activation mediates kidney ischemia/reperfusion injury. J. Clin. Invest 2007;117:2847-2859.
McGettrick A F, O'Neill LA. The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction. Mol. Immunol 2004; 41: 577-582.
Goldstein DR, Tesar BM, Akira S. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J. Clin. Invest 2003;111:1571-1578.
Chen L, Wang T, Zhou P, et al. TLR engagement prevents transplantation tolerance. Am. J. Transplant 2006;6: 2282-2291.
Walker WE, Nasr IW, Camirand G, Tesar BM, Booth CJ, Goldstein DR. Absence of innate MyD88 signaling promotes inducible allograft acceptance. J. Immunol 2006;177: 5307-5316.
Tesar BM, Zhang J, Goldstein DR. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of My D88, a Toll-like receptor signal adaptor protein. Am. J. Transplant 2004; 4:1429-1439.
Rouschop KMA, Leemans JC. Ischemia–reperfusion treatment: opportunities point to modulation of the inflammatory response. Kidney Int 2008;73:1333-35.
Cao CC, Ding XQ, Ou ZL, et al. In vivo transfection of NF-kappaB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats. Kidney Int 2004;65:834–845.
Eickelberg O, Seebach F, Riordan M, et al. Functional activation of heat shock factor and hypoxia-inducible factor in the kidney. J Am Soc Nephrol 2002;13:2094–2101.
Shreeniwas R, Koga S, Karakurum M, et al. Hypoxia-mediated induction of endothelial cell interleukin-1 alpha: An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992; 90: 2333−2339.
Loverre A, Divella C, Castellano G, et al. T helper 1, 2 and 17 cell subsets in renal transplant patients with delayed graft function. Transpl Int 2011;24(3):233-42.
Schmedtje JF, Jr, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF kappa p65 transcription factor in human vascular endothelia cells. J Biol Chem 1997; 272: 601−608.
Arnould T, Michiels C, Remacle J. Increased PMN adherence on endothelial cells after hypoxia: Involvement of PAF, CD18/ CD11b, and ICAM 1. Am J Physiol 1993; 264: C1102−C1110.
Thurman JM, Ljubanovic D, Royer PA, et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 2006;116:357–368.
Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int 2003;63:134–142.
David S, Biancone L, Caserta C, Bussolati B, Cambi V, Camussi G. Alternative pathway complement activation induces proinflammatory activity in human proximal tubular epithelial cells. Nephrol Dial Transplant 1997;12:51–56.
Yamada K, Miwa T, Liu J, Nangaku M, Song WC. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004;172:3869–3875.
Koo DH, Welsh KI, Roake JA, Morris PJ, Fuggle SV. Ischemia/Reperfusion Injury in Human Kidney Transplantation. Am J Pathol 1998;153(2):557–566.
De Vries B, Kohl J, Leclercq WK, et al. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 2003;170:3883–3889.
Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA, Griffin MD. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int 2007;71:619–628.
Schlichting CL, Scharecka WD, Weis M. Renal Ischemia–Reperfusion Injury: New Implications of Dendritic Cell–Endothelial Cell Interactions. Transplantation Proceedings 2006;38(3):670-673.
Savransky V, Molls RR, Burne-Taney M, Chien CC, Racusen L, Rabb H. Role of the T-cell receptor in kidney ischemia-reperfusion injury. Kidney Int 2006;69:233–238.
Hochegger K, Schatz T, Eller P, et al. Role of alpha/beta and gamma/delta T cells in renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2007;293:F741–747.
Renner B, Strassheim D, Amura CR, et al. B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J Immunol 2010;185(7):4393-400.
Rabb H, Daniels F, O’Donnell M, et al. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol Renal Physiol 2000;279:F525–531.
Burne MJ, Daniels F, El Ghandour A, et al. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001;108:1283–1290.
Land W, Schneeberger H, Schleibner S, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants Transplantation.1994;57: 211-217.
Land WG. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 2005;79:505-514.
Yokota N, Burne-Taney M, Racusen L, Rabb H. Contrasting roles for STAT4 and STAT6 signal transduction pathways in murine renal ischemiareperfusion injury. Am J Physiol Renal Physiol 2003;285:F319–325.
Nankivell BJ, Alexander SI. Rejection of the Kidney Allograft. N Engl J Med 2010;363:1451-62.
Takada M, Chandraker A, Ndeau KC, Sayegh M, Tilney NL. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest 1997; 100: 1199−1203.
Alegre ML, Chen L, Wang T, Ahmed E, Wang CR, Chong A. Antagonistic effect of Toll-like receptor signaling and bacterial infections on transplantation tolerance. Transplantation 2009;87: S77-S79.
Fischereder M, Schroppel B. The role of chemokines in acute renal allograft rejection and chronic allograft injury. Front Biosci 2009;14:1807-14.
Melter M, McMahon G, Fang J, Ganz P, Briscoe DM. Current understanding of chemokine involvement in allograft transplantation. Pediatric Transplantation 1999; 3(1):10–21.
Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 1996;10:709−720.
Baldwin AS, Jr. The NF kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 1996;14:649−681.
Morooka H, Bonventre JV, Pombo CM, Kyriakis JM, Force T. Ischemia and reperfusion enhance ATF-2 and c-Jun binding to cAMP response elements and to an AP-1 binding site from the c-jun promoter. J Biol Chem 1995; 270:30084−30092.
Grewal IS, Borrow P, Pamer EG, Oldstone MB, Flavell RA. The CD40- CD154 system in anti-infective host defense. Curr Opin Immunol 1997;9:491−497.
Todo S, Nery J, Yanaga K, Podesta L, Gordon RD, Starzl TE. Extended preservation of human liver grafts with UW solution. JAMA 1989;261:711-714.
Marzi I, Knee J, Buhren V, Menger M, Trentz O. Reduction by superoxide dismutase of leukocyte-endothelial adherence after liver transplantation Surgery 1992;111:90-97.
Janssen H, Janssen PH, Broelsch CE. Value of energy substrates in HTK and UW to protect human liver endothelial cells against ischemia and reperfusion injury. Eur Surg Res 2004;36:26-32.
Carrier M, Blaise G, Belisle S, et al. Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation. J Heart Lung Transplant 1999;18:664-667.
Inman SR, Davis NA, Mazzone ME, Olson KM, Lukaszek VA, Yoder KN. Simvastatin and L-arginine preserve renal function after ischemia/reperfusion injury. Am J Med Sci 2005;329:13-17.
Brauer RB, Marx T, Ulm K, Stangl MJ. Effect of perioperative administration of a drug regimen on the primary function of human renal allografts. Transplant Proc 2010;42(5):1523-5.
Treska V, Kobr J, Hasman D, et al. Ischemia reperfusion injury in kidney transplantation from non heart beating donor, do antioxidants or antinflammatory drugs play an role? Bratisel Lek Listy 2009;110 (3):133-136.
Danilovic A, Lucon AM, Srougi M, et al. Protective Effect of N-acetylcysteine on Early Outcomes of Deceased Renal Transplantation. Transplant Proc 2011;43(5):1443-9.
Gonwa TA, Mai ML, Melton LB, et al. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody. Clinical Transplantation 2002;16(2):144–149.
Aiello S, Cassis P, Mister M, et al. Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation. Transpl Int 2011;24(8):829-38.
Schenker P, Ozturk A, Vonend O, et al. Single-dose thymoglobulin induction in living-donor renal transplantation. Ann Transplant 2011;16(2):50-8.
Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001;71:460-468.
Gandolfo MT, Jang HR, Bagnasco SM, et al. Mycophenolate mofetil modifies kidney tubular injury and Foxp3+ regulatory T cell trafficking during recovery from experimental ischemia-reperfusion. Transpl Immunol 2010;23(1-2):45-52.
Leemans JC, Stokman G, Claessen N, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005;115:2894–2903.
Shigeoka AA, Holscher TD, King AJ, et al. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and independent pathways. J Immunol 2007;178:6252–6258.
Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/reperfusion injury., J Clin Invest 2007; 117: 2847–2859.
Kruger B, Krick S, Dhillon N, et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA 2009;106:3390-3395.
Rusai DS K, Baumann M, Wagner B, et al. Toll-like Receptor 2 and 4 in Renal Ischemia/Reperfusion Injury. Ped Nephrol 2010;25(5):853-60.
Liu M, Gu M, Xu D, Lv Q, Zhang W, Wu Y. Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury. Transplant Proc 2010;42(5):1539-44.
Rabb H, O'Meara YM, Maderna P, Coleman P, Brady HR. Leukocytes, cell adhesion molecules and ischemic acute renal failure. Kidney Int 1997;51:1463−1468.
Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448−1460.
Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA. Alphamelanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 1997;99:1165−1172.
Kelly KJ, Williams WW, Colvin RB, et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996;97:1056–1063.
Nemoto T, Burne MJ, Daniels F, et al. Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int 2001;60:2205–2214.
Rabb H, Mendiola CC, Dietz J, et al. Role of CD11a and CD11b in ischemic acute renal failure in rats. Am J Physiol 1994;267:F1052–1058.
Haug CE, Colvin RB, Delmonico FL, et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 1993;55:766–772. discussion 772-763.
Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007;7(7):1770-1777.
Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004;66:486–491.
Hanto DW, Maki T, Yoon MH, et al. Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. Am J Transplant 2010;10(11):2421-30.
Sandovici M, Henning RH, van Goor H, et al. Systemic gene therapy with interleukin-13 attenuates renal ischemia–reperfusion injury. Kidney Int 2008;73:1364–1373.
Pascher A, Klupp J. Biologics in the treatment of transplant rejection and ischemia/perfusion injury: new applications for TNF a inhibitors. Bio Drugs 2005;19(4):211-31.
Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146−151.
Thurman JM, Royer PA, Ljubanovic D, et al. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol 2006;17:707–715.
Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int 2003;63:134–142.
de Vries B, Kohl J, Leclercq WK, et al. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 2003;170:3883–3889.
Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion, injury. Transplantation 2003;76:1594-1599.
Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001;281:F693-706.
Hackstein H, Taner T, Zahorchak AF, et al. Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003;101(11)4457-4463.
Boone DL, Turer EE, Lee EG, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004;5:1052-1060.
Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992;257:792−795.
Chandraker A, Takada M, Nadeau KC, et al. CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Kidney Int 1997;52:1678–1684.
Franklin SC, Moulton M, Sicard GA, Hammerman MR, Miller SB. Insulinlike growth factor I preserves renal function postoperatively. Am J Physiol 1997;272:F257−F259.
Miller SB, Martin DR, Kissane J, Hammerman MR. Hepatocyte growth factor accelerates recovery from acute ischemic renal injury in rats. Am J Physiol 1994;266(2):F129-34.
Nakatani T, Kim T, Uchida J, Kumata N, Kawashima H, Sugimura K. Hepatocyte growth factor ameliorates renal hemodynamic disorder after ischemia/reperfusion. Int J Mol Med 2002;10(2):217-19.
Gianello P, Carlier M, Jamart J, et al. Effect of 1-28 alpha-h atrial natriuretic peptide on acute renal failure in cadaveric renal transplantation. Clin Transpl 1995;9:481−489.
Chujo K, Ueno M, Asaga T, Sakamoto H, Shirakami G, Ueki M. Atrial natriuretic peptide enhances recovery from ischemia/reperfusion-induced renal injury in rats. J Biosci Bioeng 2010;109(6):526-30.
Chujo K, Ueki M, Asaga T, Taie S. Atrial natriuretic peptide attenuates ischemia/reperfusion-induced renal injury by reducing neutrophil activation in rats. Tohoku J Exp Med 2008;215(3):257-66.
Moriyama M, Tanaka T, Suzuki K. Renal protective effects of erythropoietin on ischemic reperfusion injury. Hinyokika Kiyo 2010;56(8):473-9.
Martinez F, Kamar N, Pallet N, et al. High Dose Epoetin Beta in the First Weeks Following Renal Transplantation and Delayed Graft Function: Results of the Neo-PDGF Study. American Journal of Transplantation 2010;10(7):1695–1700.
Lutz J, Thürmel K, Heemann U. Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation. Journal of Inflammation 2010;7(27):1-8.
- Abstract Viewed: 252 times
- PDF Downloaded: 227 times